Navigation Links
Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results
Date:8/6/2009

candidate; the potential for adverse safety findings relating to Contrave or Empatic to delay or prevent regulatory approval or commercialization, or result in product liability claims, including serious adverse events that are not characterized by clinical investigators as possibly related to Contrave; the third parties on whom Orexigen relies to assist with the development programs for Contrave or Empatic, including clinical investigators, contract laboratories, clinical research organizations and manufacturing organizations, may not successfully carry out their contractual duties or obligations or meet expected deadlines, and the quality or accuracy of the data or materials generated by such third parties may be of insufficient quality to include in the Company's regulatory submissions; the ability of Orexigen and its licensors to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Information included herein is based on the Company's review and evaluation of the clinical data. All conclusions and determinations contained herein are subject to the Company's further analysis of the clinical data. The ultimate determination of the safety and efficacy of Contrave and Empatic will be made by the FDA and other relevant regulatory authorities.

                            Orexigen Therapeutics, Inc.
 
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Orexigen(R) Therapeutics Prices Public Offering of Common Stock
2. Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock
3. Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R)
4. Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer
5. Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors
6. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
7. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
8. Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 6
9. Quark Pharmaceuticals to Participate in IBCs Oligonucleotide Therapeutics: From Concept to Implementation Conference
10. United Therapeutics Corporation Reports Second Quarter 2009 Financial Results
11. Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... AGA Medical Corporation announced,today that it received European ... (ACP). The ACP provides an innovative, minimally,invasive solution for ... intended use will be for the non-surgical occlusion of ... "The ACP is an important addition to the ...
... Scientists at UT Southwestern Medical Center have determined that the ... immune system how to fight off repeated infections of the ... Dec. 15 issue of the Journal of Immunology , ... and anti-viral therapies. , Typically, when a person is ...
... helped,explain how our brains build meaningful images from the bits ... Louisville Grawemeyer Award for Psychology. , Anne ... Princeton University , was selected for the ninth Grawemeyer,psychology ... Treisman, a cognitive psychologist, proposed in 1980 that ...
... immigrants in Oslo. Compared with Norwegians, the differences are also ... diseases. This is shown in a new report from the ... groups were compared with each other and the ethnic Norwegian ... care better. , The five immigrant groups in this ...
... The statistics for sexual assault are unsettling; the Department ... will be the victim of attempted or actual sexual ... researchers from two universities, including the University of Missouri, ... drug-facilitated sexual assault and fail to recognize the risk ...
... Center ranks No. 1 nationwide for the speed with which heart ... Cardiovascular Data Registry (NCDR). , ... (Vocus) December 2, ... speed with which heart attack patients are treated using balloon angioplasty, ...
Cached Medicine News:Health News:AGA Medical Receives European CE Mark Approval for AMPLATZER(R) Cardiac Plug 2Health News:Interferon needed for cells to 'remember' how to defeat a virus, UT Southwestern researchers report 2Health News:Theory of How Brain Builds Images Earns Grawemeyer Prize 2Health News:Large health differences between population groups in Norway 2Health News:Large health differences between population groups in Norway 3Health News:Large health differences between population groups in Norway 4Health News:MU researcher calls for increase in sexual assault awareness programs on college campuses 2Health News:MU researcher calls for increase in sexual assault awareness programs on college campuses 3Health News:UCSF Medical Center Leads Nation in ER Heart Attack Care 2Health News:UCSF Medical Center Leads Nation in ER Heart Attack Care 3
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... 2,050,000 shares of its common stock and Series ... common stock.  Funds under the management of QVT ...
(Date:12/24/2014)... , Dec. 23, 2014  Advanced Medical ... company engaged primarily in the development of brachytherapy ... applications, today announced that it has filed a ... and Drug Administration ("FDA") for marketing clearance for ... 513(f)(2) of the U.S. Food, Drug and Cosmetic ...
(Date:12/24/2014)... 23, 2014   Assurex Health, a personalized ... healthcare providers for behavioral health and chronic pain ... million in equity financing from new and existing ... President and Chief Executive Officer. The ... of Assurex Health,s GeneSight ®  products.  ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... 2011 Savvy executives in pharmaceutical commercial functions ... in today,s volatile healthcare environment. Quantitative and qualitative ... for increased resources, justify costs, or signal necessary ... presidents, directors, and managers tasked with right-sizing investment ...
... Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the ... European Medicines Agency (EMA) has granted orphan designation for ... B. Orphan designation in the European Union provides several ... launch and access to the central authorization procedure. ...
Cached Medicine Technology:Pharmaceutical Investment & Cost Benchmarks Accessed Quickly Through Best Practices, LLC's New Database Search Function 2Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy 2
... Dehydroepiandrosterone (DHEA) is produced in the adrenal ... gonads [1,2,3]. DHEA serves as a precursor ... relatively weak androgenic activity, estimated at ~10% ... peripubertal children and in adult women, DHEA ...
... testosterone exists as unbound or free testosterone. ... SHBG with high affinity [1], while the ... the albumin-bound and free fractions may be ... action. Measurement of the free or unbound ...
... primary active hormone synthesized within the follicular ... is synthesized via a series of steps ... cells, (ii) iodination of tyrosine residues in ... 3-monoiodotyrosine and 3,5-diiodotyrosine (MIT and DIT), and ...
... protein-3 (IGFBP-3) is the main binding protein for ... component of the ~150 kDa ternary complex. This ... or IGF-II and ALS, allowing IGFBP-3, along with ... The molar concentration of IGFBP-3 in normal serum ...
Medicine Products: